ES2111047T3 - Metodos para la deteccion de metastasis de carcinomas mediante la amplificacion de los acidos nucleicos. - Google Patents

Metodos para la deteccion de metastasis de carcinomas mediante la amplificacion de los acidos nucleicos.

Info

Publication number
ES2111047T3
ES2111047T3 ES92305862T ES92305862T ES2111047T3 ES 2111047 T3 ES2111047 T3 ES 2111047T3 ES 92305862 T ES92305862 T ES 92305862T ES 92305862 T ES92305862 T ES 92305862T ES 2111047 T3 ES2111047 T3 ES 2111047T3
Authority
ES
Spain
Prior art keywords
methods
metastasis
carcinomas
amplification
detection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92305862T
Other languages
English (en)
Inventor
Mark R Green
Ernest S Kawasaki
Robert E Sobol
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
University of California Berkeley
University of California San Diego UCSD
Original Assignee
F Hoffmann La Roche AG
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24892478&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2111047(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG, University of California Berkeley, University of California San Diego UCSD filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2111047T3 publication Critical patent/ES2111047T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

SE SUMINISTRA METODOS PARA DETECTAR LAS METASTASIS DE UN CARCINOMA DE UN TEJIDO DEL CUERPO SELECCIONADO O EN UN FLUIDO. ESTOS METODOS OFRECEN UNA SENSIBILIDAD MEJORADA COMPARADOS CON LOS METODOS DE DIAGNOSTICOS ANTERIORES. EN UNA CONFORMACION DE LA INVENCION, LAS SECUENCIAS DEL ACIDO NUCLEICOS ASOCIADAS CON EL CARCINOMA OBJETO SON IDENTIFICADAS PARA DETECTAR CUALQUIER MORBILIDAD RESIDUAL MINIMA EN CARCINOMAS DE PULMON. EL METODO UTILIZA TECNICAS DE AMPLIFICACION DEL ACIDO NUCLEICO, PREFERIBLEMENTE, LA REACCION DE LA CADENA DE POLIMERASA.
ES92305862T 1991-06-26 1992-06-25 Metodos para la deteccion de metastasis de carcinomas mediante la amplificacion de los acidos nucleicos. Expired - Lifetime ES2111047T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72006191A 1991-06-26 1991-06-26

Publications (1)

Publication Number Publication Date
ES2111047T3 true ES2111047T3 (es) 1998-03-01

Family

ID=24892478

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92305862T Expired - Lifetime ES2111047T3 (es) 1991-06-26 1992-06-25 Metodos para la deteccion de metastasis de carcinomas mediante la amplificacion de los acidos nucleicos.

Country Status (9)

Country Link
US (2) US5543296A (es)
EP (1) EP0520794B1 (es)
JP (1) JP3898233B2 (es)
AU (1) AU662906B2 (es)
CA (1) CA2072314C (es)
DE (1) DE69223284T2 (es)
DK (1) DK0520794T3 (es)
ES (1) ES2111047T3 (es)
GR (1) GR3026153T3 (es)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU662906B2 (en) * 1991-06-26 1995-09-21 F. Hoffmann-La Roche Ag Methods for detection of carcinoma metastases by nucleic acid amplification
CA2148350A1 (en) * 1992-10-29 1994-05-11 Carlo Croce Methods of detecting micrometastasis of prostate cancer
US5674682A (en) * 1992-10-29 1997-10-07 Thomas Jefferson University Nucleic acid primers for detecting micrometastasis of prostate cancer
US5641672A (en) * 1993-06-09 1997-06-24 The Trustees Of Columbia University In The City Of New York Cloning and uses of the genetic locus bcl-6
US5601990A (en) * 1994-09-13 1997-02-11 Thomas Jefferson University Methods of diagnosing colorectal tumors and metastasis thereof
US5561041A (en) * 1993-11-12 1996-10-01 The Johns Hopkins University School Of Medicine Nucleic acid mutation detection by analysis of sputum
US6235470B1 (en) 1993-11-12 2001-05-22 The Johns Hopkins University School Of Medicine Detection of neoplasia by analysis of saliva
US6025127A (en) * 1994-01-14 2000-02-15 The Johns Hopkins University School Of Medicine Nucleic acid mutation detection in histologic tissue
CA2187775A1 (en) * 1994-04-15 1995-10-26 Aaron E. Katz Method for molecular staging of prostate cancer
WO1996021042A2 (en) * 1995-01-04 1996-07-11 Trustees Of Boston University Primers for the pcr amplification of metastatic sequences
EP0871768B1 (en) * 1995-03-17 2004-07-07 John Wayne Cancer Institute Detection of melanoma metastases with a multiple marker assay
EP0904397A4 (en) * 1996-04-16 2003-01-29 Smithkline Beecham Corp METHOD FOR DETECTION OF THE PROSTATE SPECIFIC ANTIGEN USED FOR MONITORING AND DIAGNOSING PROSTATE CANCER
EP2264045B1 (en) * 1996-08-14 2015-10-21 Life Technologies Corporation Stable compositions for nucleic acid amplification and sequencing
US6287822B1 (en) 1997-08-05 2001-09-11 Transgenomic, Inc. Mutation detection method
WO1998024935A1 (en) * 1996-12-06 1998-06-11 Urocor, Inc. Diagnosis of disease state using mrna profiles
US7332270B1 (en) 1997-03-24 2008-02-19 Urocor, Inc. Diagnosis of disease state using mRNA profiles in peripheral leukocytes
US6190857B1 (en) * 1997-03-24 2001-02-20 Urocor, Inc. Diagnosis of disease state using MRNA profiles in peripheral leukocytes
DE69840669D1 (de) * 1997-04-10 2009-04-30 Stichting Katholieke Univ Pca3, pca3-gene und verfahren zu ihrer verwendung
US6300088B1 (en) 1997-11-24 2001-10-09 Duke University Method of detecting prostate specific antigen
DE19813788A1 (de) * 1998-03-27 1999-10-07 Deutsches Krebsforsch Nachweisverfahren für Tumorzellen
AU3762699A (en) * 1998-04-27 1999-11-16 Pacific Northwest Cancer Foundation (nr-cam) gene, nucleic acids and nucleic acid products for therapeutic and diagnostic uses for tumors
EP1084276A1 (de) * 1998-06-10 2001-03-21 Memorec Medical Molecular Research Cologne Stoffel GmbH Träger für die parallele identifizierung und erstellung von transkriptionsprofilen von polynucleinsäuren
US7226731B1 (en) 1998-07-24 2007-06-05 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services PB 39, a gene dysregulated in prostate cancer, and uses thereof
EP1100903A1 (en) * 1998-07-24 2001-05-23 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Pb 39, a gene dysregulated in prostate cancer, and uses thereof
US6455692B1 (en) 1998-08-04 2002-09-24 Transgenomic, Inc. Method of concentrating polynucleotides using MIPC
WO2000008212A1 (en) * 1998-08-07 2000-02-17 Cellay, Llc Gel microdrops in genetic analysis
EP1151142A2 (en) * 1999-01-28 2001-11-07 Gen-Probe Incorporated Nucleic acid sequences for detecting genetic markers for cancer in a biological sample
EP1222266B1 (en) 1999-09-29 2006-03-29 Diagnocure Inc. Pca3 messenger rna in benign and malignant prostate tissues
US6203992B1 (en) 1999-10-15 2001-03-20 Abbott Laboratories Nucleic acid primers and probes for detecting tumor cells
US6902890B1 (en) * 1999-11-04 2005-06-07 Diadexus, Inc. Method of diagnosing monitoring, staging, imaging and treating cancer
WO2001034837A1 (en) * 1999-11-12 2001-05-17 Limeart Limited Diagnosis and prognosis of cancer through detection of the tumor antigen 17-1a by rt-pcr
CA2404431C (en) * 2000-03-27 2011-06-07 Thomas Jefferson University Guanylyl cyclase c in the detection of stomach and esophageal cancers
AU2001253852A1 (en) * 2000-03-31 2001-10-15 Institut Gustave Roussy Preprocalcitonin as tumor rejection antigen precursor and uses thereof
US7829276B2 (en) * 2000-09-18 2010-11-09 Thomas Jefferson University Methods of using CRCA-1 as a stomach and esophageal cancer marker
US6897024B2 (en) 2001-05-31 2005-05-24 Stichting Katholieke Universiteit More Particularly The University Medical Centre Nijmegen Nucleic acid molecules comprising the promoter for PCA3, and uses thereof
CA2466896A1 (en) 2001-09-06 2003-03-20 Adnagen Ag Method and diagnosis kit for selecting and or qualitative and/or quantitative detection of cells
WO2003044224A1 (de) * 2001-11-22 2003-05-30 Adnagen Ag Diagnose-kit, dns-chip sowie verfahren zur diagnostik oder behandlungskontrolle bei hodenkrebs
US8980568B2 (en) 2001-10-11 2015-03-17 Aviva Biosciences Corporation Methods and compositions for detecting non-hematopoietic cells from a blood sample
US8986944B2 (en) 2001-10-11 2015-03-24 Aviva Biosciences Corporation Methods and compositions for separating rare cells from fluid samples
US7026120B2 (en) * 2002-04-15 2006-04-11 Abbott Laboratories Probes for detecting tumor cells
GR1004303B (el) * 2002-11-05 2003-07-30 Ελευθεριος Γεωργακοπουλος ΝΕΑ ΜΕΘΟΔΟΣ ΑΝΙΧΝΕΥΣΗΣ ΤΟΥ ΚΑΡΚΙΝΙΚΟΥ ΜΕΜΒΡΑΝΙΚΟΥ ΑΝΤΙΓΟΝΟΥ Ep-Cam ΚΑΙ ΠΡΟΣΔΙΟΡΙΣΜΟΣ ΚΥΚΛΟΦΟΡΟΥΝΤΩΝ ΜΙΚΡΟΜΕΤΑΣΤΑΤΙΚΩΝ ΚΑΡΚΙΝΙΚΩΝ ΚΥΤΤΑΡΩΝ ΣΤΟ ΠΕΡΙΦΕΡΙΚΟ ΑΙΜΑ ΑΣΘΕΝΩΝ (ΚΑΙ ΣΕ ΙΣΤΟΥΣ) ΜΕ ΚΑΡΚΙΝΟ ΕΠΙΘΗΛΙΑΚΗΣ ΠΡΟΕΛΕΥΣΗΣ
EP1572105B1 (en) * 2002-11-14 2011-08-31 John Wayne Cancer Institute Detection of micro metastasis of melanoma and breast cancer in paraffin-embedded tumor draining lymph nodes by multimaker quantitative rt-pcr
US8039218B2 (en) 2002-11-14 2011-10-18 John Wayne Cancer Institute Detection of cancer cells in body fluids
EP1592809B1 (en) 2003-02-07 2013-04-10 Diagnocure Inc. Method to detect prostate cancer in a sample
WO2004094986A2 (en) 2003-04-16 2004-11-04 Handylab, Inc. System and method for electrochemical detection of biological compounds
EP2290073A3 (en) 2004-05-28 2011-08-31 Asuragen, Inc. Methods and compositions involving microRNA
ES2301268B1 (es) * 2004-10-25 2009-05-01 Centro De Investigacion Biomolecular Aplicada Salamanca, S.L. Empleo del gen slug, o de sus productos de replicacion, transcripcion o expresion, en la identificacion, diagnostico, prevencion o tratamiento de la diseminacion del cancer y/o desarrollo de metastasis.
EP2302055B1 (en) 2004-11-12 2014-08-27 Asuragen, Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
CA2491067A1 (en) 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
US20060161076A1 (en) * 2005-01-06 2006-07-20 Diamics, Inc. Systems and methods for collection of cell clusters
US20060189893A1 (en) * 2005-01-06 2006-08-24 Diamics, Inc. Systems and methods for detecting abnormal cells
US20070292882A1 (en) * 2006-06-16 2007-12-20 Sysmex Corporation Method and apparatus for detecting cancer cell
EP2041299A4 (en) 2006-07-14 2010-01-13 Aviva Biosciences Corp METHOD AND COMPOSITIONS FOR DETECTION OF RARE CELLS FROM A BIOLOGICAL SAMPLE
US20080131878A1 (en) * 2006-12-05 2008-06-05 Asuragen, Inc. Compositions and Methods for the Detection of Small RNA
WO2008073915A2 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. Micrornas differentially expressed in leukemia and uses thereof
EP2104734A2 (en) * 2006-12-08 2009-09-30 Asuragen, INC. Mir-20 regulated genes and pathways as targets for therapeutic intervention
CA2671270A1 (en) * 2006-12-29 2008-07-17 Asuragen, Inc. Mir-16 regulated genes and pathways as targets for therapeutic intervention
US20090232893A1 (en) * 2007-05-22 2009-09-17 Bader Andreas G miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
AU2008261951A1 (en) * 2007-06-08 2008-12-18 Asuragen, Inc. miR-34 regulated genes and pathways as targets for therapeutic intervention
WO2009036332A1 (en) 2007-09-14 2009-03-19 Asuragen, Inc. Micrornas differentially expressed in cervical cancer and uses thereof
WO2009052386A1 (en) * 2007-10-18 2009-04-23 Asuragen, Inc. Micrornas differentially expressed in lung diseases and uses thereof
WO2009070805A2 (en) 2007-12-01 2009-06-04 Asuragen, Inc. Mir-124 regulated genes and pathways as targets for therapeutic intervention
WO2009126726A1 (en) * 2008-04-08 2009-10-15 Asuragen, Inc Methods and compositions for diagnosing and modulating human papillomavirus (hpv)
WO2009137807A2 (en) 2008-05-08 2009-11-12 Asuragen, Inc. Compositions and methods related to mirna modulation of neovascularization or angiogenesis
JP5585811B2 (ja) * 2009-01-23 2014-09-10 国立大学法人金沢大学 肺癌、肺癌合併ｌｅｍｓ及びｌｅｍｓの検査方法
WO2013040251A2 (en) 2011-09-13 2013-03-21 Asurgen, Inc. Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
KR101762340B1 (ko) 2015-12-09 2017-07-27 주식회사 포스코 수지 조성물 및 이를 이용한 흑색 수지 강판, 및 그 제조방법
GB201802312D0 (en) * 2018-02-13 2018-03-28 Vib Vzw Melanoma disease stratification

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965188A (en) * 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
WO1991009944A2 (en) * 1989-12-22 1991-07-11 F.Hoffmann-La Roche Ag High temperature reverse transcriptases
US5085983A (en) * 1988-08-19 1992-02-04 City Of Hope Detection of human tumor progression and drug resistance
US5024934A (en) * 1988-03-14 1991-06-18 The Board Of Regents, The University Of Texas System Detection of minimal numbers of neoplastic cells carrying DNA translocations by DNA sequence amplification
US5057410A (en) * 1988-08-05 1991-10-15 Cetus Corporation Chimeric messenger RNA detection methods
AU662906B2 (en) * 1991-06-26 1995-09-21 F. Hoffmann-La Roche Ag Methods for detection of carcinoma metastases by nucleic acid amplification

Also Published As

Publication number Publication date
GR3026153T3 (en) 1998-05-29
EP0520794A1 (en) 1992-12-30
CA2072314A1 (en) 1992-12-27
DE69223284T2 (de) 1998-06-25
AU662906B2 (en) 1995-09-21
US5766888A (en) 1998-06-16
DK0520794T3 (da) 1998-04-27
EP0520794B1 (en) 1997-11-26
JPH05269000A (ja) 1993-10-19
JP3898233B2 (ja) 2007-03-28
CA2072314C (en) 2007-07-31
US5543296A (en) 1996-08-06
DE69223284D1 (de) 1998-01-08
AU1846592A (en) 1993-01-07

Similar Documents

Publication Publication Date Title
ES2111047T3 (es) Metodos para la deteccion de metastasis de carcinomas mediante la amplificacion de los acidos nucleicos.
ES2191018T3 (es) Procedimiento para detectar micrometastasis de cancer de prostata.
ATE225369T1 (de) Doppelsträngige peptidenukleinsäuren
ES2131038T3 (es) Procedimiento inmunologico para detectar anticuerpos dirigidos contra la transglutaminasa tisular (ttg), utilizacion de la ttg para fines de diagnostico y de control de terapia y agente farmaceutico oral que contiene la ttg.
ES2072900T3 (es) Expresion elevada de proteinas en levadura.
FI860744A7 (fi) Liuosfaasissa tehtävä kaksoishybridisaatiokoe polynukleotidisekvenssien detektoimiseksi.
BR0313414A (pt) ácidos nucléicos imunoestimulatórios
DK1103564T3 (da) Cancerantigener baseret på tumorsuppressorgen WT1-produkt
FI892131L (fi) Analoger till underenheter av bordetellatoxin, vilka haerstammar fraon hybrid-dna.
ES2186671T3 (es) Adn del sitio de integracion del virus asociado a adenovirus humano y usos del mismo.
IT8026043A0 (it) Sistema substrato di amplificazione della luminescenza chimica perimmuno-chimica.
NL161861B (nl) Stalen pijp met een uitwendige bekleding.
FR2694768B1 (fr) Séquences d'oligonucléotides pour la détection spécifique de mollicutes par amplication de gènes conservés.
ATE184787T1 (de) Therapeutische kombinationen
DK139628B (da) Vandigt boreslam.
ES2059305T5 (es) Proteina del virus de la seudorrabia.
IT7921438A0 (it) Procedimento per la conservazione di un fango attivo.
GR900100354A (el) Συστημα και μεθοδος βασιζομενα σε νουκλεικα οξεα για την ανιχνευση pneumocystis carinii σε προιοντα αιματος.
ES2059444T3 (es) Procedimiento para la obtencion de acroleinas alfa,beta-substituidas.
IT8125118A0 (it) Sistema per la rivelazione di bersagli.
CY1112454T1 (el) Ανασυνδυασμενη καρβοξυπεπτιδαση β
CH549756A (de) Brennkammerberohrung.
SU613113A1 (ru) Способ гидроизол ции болтовых отверстий тюбингов сборной обделки коллекторных тоннелей
FR2117352A5 (en) 2,4,5,6,7-pentachloro-benzoxazole - acaricide and fungicide
EA199900726A1 (ru) Синтетические hiv gag гены

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 520794

Country of ref document: ES